2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5968 TPO-integrated benefit score predicts the efficacy of avatrombopag on platelet engraftment after haplo-HSCT: Secondary analysis of a randomized clinical trial

Hai-Xia Fu, MD, Zhuo-Yu An, MD2, Yuanyuan Zhang3, Qiusha Huang4, Erlie Jiang5, Aiming Pang6, Xiena Cao7, Huibo Li8, Yuyang Zhao9, Xiaowei Chen10, Baoquan Song11, Lihua Sun12, Yang Cao13, Jun Kong14, Zhengli Xu15, Xiaolu Zhu, MD16, Ting-ting Han, MD17, Fengmei Zheng18, Fengrong Wang19, Xuying Pei20, Yao Chen21, Chenhua Yan22, Jingzhi Wang23, Zhidong Wang24, Jing Liu25, Wei Sun26, Yun He, MD27, Leqing Cao28, Dao-Xing Deng29, Ling Ma30, Yu-Hong Chen31, Huan Chen32, Yifei Cheng33, Yu-Qian Sun34, Meng Lv35, Xiaodong Mo36, Ying-jun Chang37, Yicheng Zhang38, Hongyu Zhang39, Fei Li40, Shunqing Wang41, Yuanbin Wu42, Shengjin Fan43, Linghui Xia44, Xiang-Yu Zhao45, Yu Wang46, Lan-Ping Xu47, Xiaojun Huang, MD,PhD48, Xiaohui Zhang, MD49
1 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
2 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
3 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
4 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
5 Department of Hematology/Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
6 Department of Hematology/Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
7 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
8 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
9 Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, Guangzhou, China
10 Department of Hematology, Guangzhou First People's Hospital, South China University of Technology/Guangzhou Medical University, Guangzhou, China, Guangzhou, China
11 Department of Hematology, First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China
12 Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China, Shenzhen, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wuhan, China
14 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
15 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
16 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
17 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
18 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
19 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
20 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
21 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
22 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
23 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
24 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
25 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
26 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
27 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
28 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
29 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
30 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
31 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
32 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
33 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
34 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
35 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
36 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
37 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
38 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
39 Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China, Shenzhen, China
40 Department of Hematology, First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China
41 Department of Hematology, Guangzhou First People's Hospital, South China University of Technology/Guangzhou Medical University, Guangzhou, China, Guangzhou, China
42 Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China, Guangzhou, China
43 Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China, Harbin, China
44 Department of Hematology, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
45 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
46 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
47 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
48 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
49 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China

Introduction

Thrombopoietin receptor agonists (TPO-RAs) effectively boost platelet (PLT) engraftment after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, validated biomarkers and predictive models to identify patients most likely to benefit from TPO-RAs remain lacking. Based on data from a prospective randomized controlled trial (RCT) , this study aims to explore baseline predictors for avatrombopag efficacy in promoting platelet engraftment after haplo-HSCT.

 

Methods 

Prespecified secondary analyses were performed on a multicenter, placebo-controlled RCT (NCT06202625) conducted at 9 Chinese tertiary hematology centers between May 13, 2024 and August 31, 2025. Eligible adults aged 18–65 received haplo-HSCT and presented PLT <20×10?/L or persistent platelet transfusion dependence on day 7 post-transplant. Subjects were randomized 1:1 to oral avatrombopag (initial 20 mg daily, max 40 mg daily to maintain PLT 50–80×10?/L) or matching placebo, administered day 7 to day 60 post-transplant. Primary endpoint: sustained PLT ≥50×10?/L for 7 consecutive days without transfusion by day 60. Key secondary endpoint: sustained PLT ≥100×10?/L at day 60. Prespecified subgroup interaction analyses were conducted, and baseline day 7 plasma TPO concentrations were tested in a subset of participants.

 

Results

Among 563 screened patients, 146 underwent randomization. 142 subjects (72 avatrombopag, 70 placebo) were treated with study medication and comprised the FAS. At day 60, the primary outcome occurred in 51 of 72 patients (70.8%) in the avatrombopag group and 47 of 70 (67.1%) in the placebo group (adjusted risk ratio 1.07, 95% confidence interval 0.86 to 1.33; absolute risk difference 3.7 percentage points, 95% CI −11.5 to 18.9; stratified P=0.55). A sustained platelet count of 100×10?/L or greater at day 60 was achieved by 38 of 72 (52.8%) patients receiving avatrombopag versus 24 of 70 (34.3%) receiving placebo (adjusted risk ratio 1.56, 95% CI 1.06 to 2.31; absolute risk difference 18.5 percentage points, 95% CI 2.5 to 34.5; stratified P=0.02).    

Baseline TPO testing was completed for 84 participants (42 per arm). Median TPO dropped more drastically in the avatrombopag group: from 1800.28 pg/mL (baseline) to 740.06 pg/mL (day 60), with a median reduction of 1060.22 pg/mL. The placebo group showed milder decline, from 1618.02 pg/mL to 961.66 pg/mL (median reduction=656.37 pg/mL). Generalized estimating equation (GEE) revealed a significant group-by-time interaction for circulating TPO (P<0.001), proving divergent longitudinal TPO variation magnitude between two arms.

We set ≤1714 pg/mL as the cutoff value for TPO stratification. This threshold, determined in our prior retrospective study, could predict the therapeutic response to avatrombopag in patients with post-transplant thrombocytopenia. Nevertheless, the single-factor TPO stratification yielded non-significant interaction (P=0.392). We constructed an equal-weight three-variable composite score (0-3 points) named the TPO-integrated benefit score, incorporating TPO ≤1714 pg/mL, age ≤42 years and CD34+ cell dose ≤5.5×106/kg. A significant treatment-by-score interaction was observed. Low-score (0-1 points) patients (n=29) obtained no clinical benefit from avatrombopag. Among high-score (2-3 points) patients (n=55), day-60 PLT ≥50×10?/L rate reached 75.0% (18/24) with avatrombopag versus 54.8% (17/31) with placebo (RR=1.37, 95%CI 0.91-2.06). The RR interaction ratio was 2.03 (95% CI 1.12–3.71) (P=0.016), indicating remarkable efficacy heterogeneity stratified by this score.

Conclusions

Avatrombopag significantly reshapes the longitudinal kinetic trajectory of circulating TPO after haplo-HSCT. The TPO-integrated benefit score serves as a simple stratification tool to guide individualized avatrombopag administration for haplo-HSCT recipients. However, a large-scale prospective trial is warranted to externally validate its predictive performance.

Hai-Xia Fu, MD: No relevant conflicts of interest to declare.